ArticleFrontiers in nutrition2026
Combined associations of the frailty index and CHG index with cardiometabolic multimorbidity: a longitudinal study from the CHARLS cohort.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Frailty and metabolic dysfunction are major contributors to cardiometabolic multimorbidity (CMM). However, the joint influence of frailty and insulin resistance on the onset of CMM is still insufficiently understood. This research aimed to examine the association between FI-CHG [a novel integrative metric combining the frailty index (FI) and the cholesterol-high-density lipoprotein-glucose (CHG) index] and incident CMM. Method: Overall, 8,543 participants aged ≥45 years without CMM at baseline from the China Health and Retirement Longitudinal Study (CHARLS) were recruited. Multivariable Cox regression models were utilized to assess the relationships between baseline FI-CHG levels and cumulative FI-CHG exposure during follow-up with the incidence of CMM. Restricted cubic spline analyses were applied to investigate potential dose-response relationships, while subgroup analyses were implemented to examine possible effect modification. Result: During a maximum follow-up of 8.0 years, CMM occurred in 1,666 participants (19.5%). The risk of CMM increased progressively across higher quartiles of the FI-CHG index. In receiver operating characteristic analyses, the FI-CHG index demonstrated a slightly better predictive performance [area under the curve (AUC) = 0.692] compared with FI or CHG alone. Longitudinal analyses further showed that participants with persistently high FI-CHG levels and those in the top tertile of cumulative FI-CHG exposure exhibited the greatest risk of developing CMM. Conclusion: Our study demonstrated that higher baseline FI-CHG and cumulative FI-CHG exposure were significantly associated with increased risk of CMM. By integrating metabolic and functional indicators, the FI-CHG index may serve as a relatively robust metric with potential clinical prospects for risk stratification of chronic multimorbidity. It may help improve early risk identification and provide evidence for preventive strategies targeting cardiometabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.